Description

Dehydroxymethylepoxyquinomicin (DHMEQ) is a potent and specific small-molecule inhibitor of the NF-κB signaling pathway. This compound matters significantly for researchers and developers in life sciences, as it provides a critical tool for modulating inflammatory and immune responses at the molecular level. It is primarily needed by pharmaceutical R&D teams, academic research institutions, and biotechnology companies focused on oncology, immunology, and inflammatory disease research.

Application

• NF-κB Pathway Research: A fundamental research tool for studying the role of NF-κB in cellular signaling, gene expression, and disease mechanisms.
• Inflammatory Disease Models: Used in preclinical studies to investigate potential therapeutic interventions for conditions like rheumatoid arthritis, asthma, and inflammatory bowel disease.
• Oncology Research: Applied in cancer cell line and animal model studies to explore the inhibition of NF-κB, which is often constitutively active in many cancers and contributes to tumor growth and survival.
• Immunology Studies: Employed to dissect the function of NF-κB in immune cell activation, differentiation, and cytokine production.
• Neuroinflammation Research: Utilized in models of neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) to study the link between chronic inflammation and neuronal damage.
• Apoptosis Induction Studies: Investigated for its role in sensitizing resistant cancer cells to apoptosis by blocking NF-κB-mediated survival signals.
• High-Throughput Screening (HTS): May serve as a reference compound or positive control in HTS campaigns targeting the NF-κB pathway.
• Mechanism of Action (MoA) Studies: Critical for validating novel drug targets and understanding the downstream effects of NF-κB inhibition in various biological contexts.

Basic Information

Product Name	Dehydroxymethylepoxyquinomicin
CAS No.	287194-40-5
Molecular Formula	C17H19NO6
Molecular Weight	333.34 g/mol
Synonyms	DHMEQ; (-)-Dehydroxymethylepoxyquinomicin; Cyclopent-3-ene-1-acetic acid, 5-[(1S,5R,6S)-6-ethenyl-3-oxo-7-oxabicyclo[3.2.1]oct-2-yl]-2-methyl-, methyl ester, (3S)-; NF-κB Activation Inhibitor IV; NF-κB Inhibitor DHMEQ; 5-[(1S,5R,6S)-6-Ethenyl-3-oxo-7-oxabicyclo[3.2.1]oct-2-yl]-2-methyl-3-cyclopentene-1-acetic acid methyl ester
EINECS	Contact for details

Quality Control

Our Dehydroxymethylepoxyquinomicin is produced under strict quality management systems to ensure batch-to-batch consistency and reliability for critical research applications. Each lot undergoes comprehensive analytical characterization, including HPLC for purity verification and structural confirmation by NMR and MS. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting identity, purity, and other relevant specifications to support your regulatory and research documentation needs.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store at -20°C or below under inert atmosphere. Allow the product to equilibrate to room temperature in a desiccator before opening to minimize moisture uptake. The compound is intended for research use only in a laboratory setting.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Meets ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.